Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 10, 2014 (13 years ago)

Muro 128 (sodium chloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Crystallization: Crystal precipitate formation and an increase in the number of complaints associated with a gritty, sand-like feeling in the eye.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Muro 128 (sodium chloride) hypertonicity ophthalmic ointment, 5%, packaged in a) 1 g tube per carton, professional sample, NDC 24208-385-01, UPC 3 24208-385-01 2; b) 1/8 oz. (3.5 g) tube per carton, NDC 24208-385-55, UPC 3 24208-385-55 5; and c) 1/4 oz. (7 g) Twin Pack, Two 1/8 oz. (3.5 g) tubes per carton, NDC 24208-385-56, UPC 3 24208-385-56 3; Bausch & Lomb Incorporated, Tampa, FL 33637.

Affected NDCs 24208-0385-01 24208-0385-55 24208-0385-56

Compare with the code on your package — it is the most precise check available.

Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Muro 128
sodium chloride
NDC 24208-0385
50 mg/g Ointment
Ophthalmic
Bausch & Lomb Incorporated OTC
Recalling firm
Bausch & Lomb, Inc.
NDC code
24208-385-01
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1410-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Bausch & Lomb, Inc.

All 2014 recalls
Class II · Moderate risk

NasalCrom (cromolyn sodium)

CGMP Deviations: Possibility of the presence of microbial contamination in the water used to manufacture this product lot.

Terminated Microbial contamination Bausch & Lomb, Inc. D-0899-2017

Other failed specification recalls from 2014

All failed specification recalls
Class II · Moderate risk

Benzonatate Capsules

Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-247-01 D-0325-2015
Class II · Moderate risk

Gabapentin Capsules

Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.

Terminated Failed specification Actavis Elizabeth LLC NDC 45963-555-11 D-0338-2015
Class II · Moderate risk

Gabapentin Capsules

Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.

Terminated Failed specification Actavis Elizabeth LLC NDC 45963-556-11 D-0337-2015
Class II · Moderate risk

Gabapentin Capsules

Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.

Terminated Failed specification Actavis Elizabeth LLC NDC 14550-513-02 D-0336-2015